CD8A and acute myeloid leukemia: In a cancer patient setting, however, WT1A or WT1B vaccination would serve to expand pre-existing populations or recruit cross-reactive CD8+ T-cell responses, respectively, and as discussed, previous studies indicated that WT1A vaccination in AML and MSD patients yielded functionally limited responses.